# QGEN — Qiagen · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** QGEN  
**Sources:** 28  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-qgen-qiagen-catalysts-narrative-risks-6125

---

## Qiagen (QGEN) — Point-in-Time Research Note (as of 2026-10-04)

**Snapshot.** Qiagen N.V. trades on the NYSE under ticker QGEN (ISIN NL0015002SN0). As of October 2, 2026 the share traded around $45.29 intraday (up ~7.7% on the day) per [[1]](https://www.ad-hoc-news.de/boerse/news/corporate-news/qiagen-stock-gains-7-7-percent-as-testing-catalyst-adds-support/70221860), or roughly $44.75 at the Oct 2 close (up ~6.45%), implying a market capitalization of about $9.2–9.3 billion [[1]](https://www.ad-hoc-news.de/boerse/news/corporate-news/qiagen-stock-gains-7-7-percent-as-testing-catalyst-adds-support/70221860), [[14]](https://stockanalysis.com/stocks/qgen/forecast/). The two sources report slightly different intraday vs. closing figures. Classification varies by source — diagnostics/research [[1]](https://www.ad-hoc-news.de/boerse/news/corporate-news/qiagen-stock-gains-7-7-percent-as-testing-catalyst-adds-support/70221860), biotechnology [[21]](https://en.wikipedia.org/wiki/Qiagen) — though the internal universe file lists it under healthcare_services.

## Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-qgen-qiagen-catalysts-narrative-risks-6125 (free to sign up)._
